Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway

Chen,Zhiguang; Xue,Jinqi; Shen,Tao; Mu,Shuai; Fu,Qin

doi:10.3892/ijmm.2015.2432

Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway

Authors:
- Zhiguang Chen
- Jinqi Xue
- Tao Shen
- Shuai Mu
- Qin Fu
View Affiliations

Affiliations: Department of Spine and Joint Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, The Seventh Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: December 11, 2015 https://doi.org/10.3892/ijmm.2015.2432
Pages: 329-338
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is known that prolonged glucocorticoid (GC) treatment results in osteoporosis. This study aimed to evaluate the protective effects of curcumin on the bones of rats with dexamethasone (DXM)-induced osteoporosis. In the present study, rats were administered DXM for 60 days to induce osteoporosis, and they were then treated with curcumin (100 mg/kg/day) for a further 60 days. H&E staining was used to observe the pathological changes in the femurs. Serum osteocalcin levels and collagen-type I fragments (CTX) were examined as bone metabolism markers. The results revealed that treatment with curcumin attenuated DXM-induced bone injury in femurs, increased the serum levels of osteocalcin and decreased the levels of CTX. In addition, in in vitro experiments, primary rat osteoblasts treated with curcumin at 0.5, 1 and 2 µM were exposed to 100 nM DXM. An MTT assay was used to determine the proliferative ability of the cells. Alkaline phosphatase activity, and the mRNA expression levels of runt‑related transcription factor 2 (Runx2), osterix, osteocalcin, collagen, type 1, alpha 1 (Col1A1) and osteonectin were detected to assess transcription factor-associated osteogenic differentiation. The mRNA and protein expression levels of osteoprotegerin (OPG) and receptor activator for nuclear factor-kappa B ligand (RANKL) were detected to assess cytokine-associated osteoclastogenesis. The results demonstrated that curcumin prevented the DXM-induced inhibition of the proliferative ability of the osteoblasts in a dose-dependent manner. In addition, curcumin upregulated the mRNA expression levels of transcription factors that favor osteoblast differentiation and increased the ratio of OPG to RANKL. Moreover, the effects of curcumin on the Wnt signaling pathway were also investigated. RT-qPCR and western blot analysis demonstrated that the Wnt signaling pathway, which was inhibited by DXM, was re-activated upon treatment with curcumin. Immunofluorescence staining revealed that curcumin restored the intranuclear staining of β-catenin in the DXM-stimulated osteoblasts. Collectively, our data demonstrate that curcumin may be a potential therapeutic agent for the treatment of GC-induced osteoporosis.

View Figures

View References

1	Buttgereit F, Burmester GR and Lipworth BJ: Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 365:801–803. 2005. View Article : Google Scholar : PubMed/NCBI
2	den Uyl D, Bultink IE and Lems WF: Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 13:233–240. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hallberg I, Bachrach-Lindström M, Hammerby S, Toss G and Ek AC: Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord. 10:1352009. View Article : Google Scholar : PubMed/NCBI
4	Cauley JA, Thompson DE, Ensrud KC, Scott JC and Black D: Risk of mortality following clinical fractures. Osteoporos Int. 11:556–561. 2000. View Article : Google Scholar : PubMed/NCBI
5	Weinstein RS: Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord. 2:65–73. 2001. View Article : Google Scholar : PubMed/NCBI
6	Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 44:1496–1503. 2001. View Article : Google Scholar
7	Adler RA and Hochberg MC: Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 163:2619–2624. 2003. View Article : Google Scholar : PubMed/NCBI
8	Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, et al: Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 23:105–109. 2005. View Article : Google Scholar : PubMed/NCBI
9	Sambrook PN, Diamond T, Ferris L, Fiatarone-Singh M, Flicker L, MacLennan A, Nowson C, O'Neill S and Greville H; Osteoporosis Australia; National Asthma Campaign: Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician. 30:793–796. 2001.PubMed/NCBI
10	Lestari ML and Indrayanto G: Curcumin. Profiles Drug Subst Excip Relat Methodol. 39:113–204. 2014. View Article : Google Scholar : PubMed/NCBI
11	Jurenka JS: Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 14:141–153. 2009.PubMed/NCBI
12	Kim WK, Ke K, Sul OJ, Kim HJ, Kim SH, Lee MH, Kim HJ, Kim SY, Chung HT and Choi HS: Curcumin protects against ovariectomy-induced bone loss and decreases osteoclastogenesis. J Cell Biochem. 112:3159–3166. 2011. View Article : Google Scholar : PubMed/NCBI
13	Folwarczna J, Zych M and Trzeciak HI: Effects of curcumin on the skeletal system in rats. Pharmacol Rep. 62:900–909. 2010. View Article : Google Scholar : PubMed/NCBI
14	Hussan F, Ibraheem NG, Kamarudin TA, Shuid AN, Soelaiman IN and Othman F: Curcumin protects against ovariectomy-induced bone changes in rat model. Evid Based Complement Alternat Med. 2012:1749162012. View Article : Google Scholar : PubMed/NCBI
15	Cho DC, Jung HS, Kim KT, Jeon Y, Sung JK and Hwang JH: Therapeutic advantages of treatment of high-dose curcumin in the ovariectomized rat. J Korean Neurosurg Soc. 54:461–466. 2013. View Article : Google Scholar
16	Yang MW, Wang TH, Yan PP, Chu LW, Yu J, Gao ZD, Li YZ and Guo BL: Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine. 18:205–213. 2011. View Article : Google Scholar
17	Chen Z, Xue J, Shen T, Ba G, Yu D and Fu Q: Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis in vivo and in vitro. Clin Exp Pharmacol Physiol. Oct 30–2015.Epub ahead of print. View Article : Google Scholar
18	Cadigan KM and Nusse R: Wnt signaling: a common theme in animal development. Genes Dev. 11:3286–3305. 1997. View Article : Google Scholar
19	Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA and Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 8:751–764. 2005. View Article : Google Scholar : PubMed/NCBI
20	Song L, Liu M, Ono N, Bringhurst FR, Kronenberg HM and Guo J: Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res. 27:2344–2358. 2012. View Article : Google Scholar : PubMed/NCBI
21	Pinson KI, Brennan J, Monkley S, Avery BJ and Skarnes WC: An LDL-receptor-related protein mediates Wnt signalling in mice. Nature. 407:535–538. 2000. View Article : Google Scholar : PubMed/NCBI
22	Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP and He X: LDL-receptor-related proteins in Wnt signal transduction. Nature. 407:530–535. 2000. View Article : Google Scholar : PubMed/NCBI
23	Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, et al: Osteoporosis-Pseudoglioma Syndrome Collaborative Group: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 107:513–523. 2001. View Article : Google Scholar : PubMed/NCBI
24	Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, et al: A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 70:11–19. 2002. View Article : Google Scholar
25	Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K and Lifton RP: High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 346:1513–1521. 2002. View Article : Google Scholar : PubMed/NCBI
26	Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P, Karmakar M, Kumari M, Chauhan LK, Patel DK, et al: Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway. ACS Nano. 8:76–103. 2014. View Article : Google Scholar : PubMed/NCBI
27	Tiwari SK, Agarwal S, Tripathi A and Chaturvedi RK: Bisphenol-A mediated inhibition of hippocampal neurogenesis attenuated by curcumin via canonical Wnt pathway. Mol Neurobiol. May 12–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
28	Chen F, Wang H, Xiang X, Yuan J, Chu W, Xue X, Zhu H, Ge H, Zou M, Feng H and Lin J: Curcumin increased the differentiation rate of neurons in neural stem cells via wnt signaling in vitro study. J Surg Res. 192:298–304. 2014. View Article : Google Scholar : PubMed/NCBI
29	He M, Li Y, Zhang L, Li L, Shen Y, Lin L, Zheng W, Chen L, Bian X, Ng HK and Tang L: Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway in medulloblastoma. Oncol Rep. 32:173–180. 2014.PubMed/NCBI
30	Cui L, Jia X, Zhou Q, Zhai X, Zhou Y and Zhu H: Curcumin affects β-catenin pathway in hepatic stellate cell in vitro and in vivo. J Pharm Pharmacol. 66:1615–1622. 2014. View Article : Google Scholar : PubMed/NCBI
31	Albaum JM, Levesque LE, Gershon AS, Liu G and Cadarette SM: Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012. Osteoporos Int. 26:2845–2852. 2015. View Article : Google Scholar : PubMed/NCBI
32	Baofeng L, Zhi Y, Bei C, Guolin M, Qingshui Y and Jian L: Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop. 81:396–401. 2010. View Article : Google Scholar : PubMed/NCBI
33	Castañeda S, Calvo E, Largo R, González-González R, de la Piedra C, Díaz-Curiel M and Herrero-Beaumont G: Characterization of a new experimental model of osteoporosis in rabbits. J Bone Miner Metab. 26:53–59. 2008. View Article : Google Scholar
34	Reid IR, Evans MC, Wattie DJ, Ames R and Cundy TF: Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int. 2:103–105. 1992. View Article : Google Scholar : PubMed/NCBI
35	Sambrook P, Birmingham J, Kempler S, Kelly P, Eberl S, Pocock N, Yeates M and Eisman J: Corticosteroid effects on proximal femur bone loss. J Bone Miner Res. 5:1211–1216. 1990. View Article : Google Scholar : PubMed/NCBI
36	Feng M, Zhang R, Gong F, Yang P, Fan L, Ni J, Bi W, Zhang Y, Wang C and Wang K: Protective effects of necrostatin-1 on glucocorticoid-induced osteoporosis in rats. J Steroid Biochem Mol Biol. 144B:455–462. 2014. View Article : Google Scholar
37	Samir SM and Malek HA: Effect of cannabinoid receptors 1 modulation on osteoporosis in a rat model of different ages. J Physiol Pharmacol. 65:687–694. 2014.PubMed/NCBI
38	Ehrlich PJ and Lanyon LE: Mechanical strain and bone cell function: a review. Osteoporos Int. 13:688–700. 2002. View Article : Google Scholar : PubMed/NCBI
39	Laan RF, Buijs WC, van Erning LJ, Lemmens JA, Corstens FH, Ruijs SH, van de Putte LB and van Riel PL: Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int. 52:5–9. 1993. View Article : Google Scholar : PubMed/NCBI
40	Reid IR and Heap SW: Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med. 150:2545–2548. 1990. View Article : Google Scholar : PubMed/NCBI
41	Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP and Teitelbaum SL: Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest. 116:2152–2160. 2006. View Article : Google Scholar : PubMed/NCBI
42	Miyazaki T, Matsunaga T, Miyazaki S, Hokari S and Komoda T: Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. J Cell Biochem. 93:503–512. 2004. View Article : Google Scholar : PubMed/NCBI
43	Wysokinski D, Pawlowska E and Blasiak J: RUNX2: A master bone growth regulator that may be involved in the DNA damage response. DNA Cell Biol. 34:305–315. 2015. View Article : Google Scholar : PubMed/NCBI
44	Sinha KM and Zhou X: Genetic and molecular control of osterix in skeletal formation. J Cell Biochem. 114:975–984. 2013. View Article : Google Scholar :
45	Komori T: Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem. 95:445–453. 2005. View Article : Google Scholar : PubMed/NCBI
46	Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR and de Crombrugghe B: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 108:17–29. 2002. View Article : Google Scholar : PubMed/NCBI
47	Zhou X, Zhang Z, Feng JQ, Dusevich VM, Sinha K, Zhang H, Darnay BG and de Crombrugghe B: Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci USA. 107:12919–12924. 2010. View Article : Google Scholar : PubMed/NCBI
48	Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, et al: A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 25:109–113. 1999. View Article : Google Scholar : PubMed/NCBI
49	Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T and Higashio K: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 234:137–142. 1997. View Article : Google Scholar : PubMed/NCBI
50	Buckley KA and Fraser WD: Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem. 39:551–556. 2002. View Article : Google Scholar
51	Kim JH, Liu X, Wang J, Chen X, Zhang H, Kim SH, Cui J, Li R, Zhang W, Kong Y, et al: Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis. 5:13–31. 2013. View Article : Google Scholar : PubMed/NCBI
52	Rossini M, Gatti D and Adami S: Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 93:121–132. 2013. View Article : Google Scholar : PubMed/NCBI
53	Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR and Fahrleitner-Pammer A: Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 97:148–154. 2012. View Article : Google Scholar
54	Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J and Liao E: Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 76:797–801. 2012. View Article : Google Scholar
55	Sutherland MK, Geoghegan JC, Yu C, Winkler DG and Latham JA: Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone. 35:448–454. 2004. View Article : Google Scholar : PubMed/NCBI
56	Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO and Lane NE: Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 58:3485–3497. 2008. View Article : Google Scholar : PubMed/NCBI
57	Bafico A, Liu G, Yaniv A, Gazit A and Aaronson SA: Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol. 3:683–686. 2001. View Article : Google Scholar : PubMed/NCBI
58	Rawadi G, Vayssière B, Dunn F, Baron R and Roman-Roman S: BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res. 18:1842–1853. 2003. View Article : Google Scholar : PubMed/NCBI
59	Mak W, Shao X, Dunstan CR, Seibel MJ and Zhou H: Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int. 85:538–545. 2009. View Article : Google Scholar : PubMed/NCBI
60	Ohnaka K, Taniguchi H, Kawate H, Nawata H and Takayanagi R: Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 318:259–264. 2004. View Article : Google Scholar : PubMed/NCBI
61	Wang FS, Ko JY, Yeh DW, Ke HC and Wu HL: Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology. 149:1793–1801. 2008. View Article : Google Scholar : PubMed/NCBI
62	Lin X, Farooqi AA and Ismail M: Recent progress in fungus-derived bioactive agents for targeting of signaling machinery in cancer cells. Drug Des Devel Ther. 9:1797–1804. 2015.PubMed/NCBI
63	Wang FS, Chuang PC, Lin CL, Chen MW, Ke HJ, Chang YH, Chen YS, Wu SL and Ko JY: MicroRNA-29a protects against glucocorticoid-induced bone loss and fragility in rats by orchestrating bone acquisition and resorption. Arthritis Rheum. 65:1530–1540. 2013. View Article : Google Scholar : PubMed/NCBI
64	Smith E and Frenkel B: Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem. 280:2388–2394. 2005. View Article : Google Scholar
65	Wang FS, Ko JY, Weng LH, Yeh DW, Ke HJ and Wu SL: Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss. Life Sci. 85:685–692. 2009. View Article : Google Scholar : PubMed/NCBI